104 related articles for article (PubMed ID: 8675981)
1. Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer.
Warren GP; Roth BJ
Indiana Med; 1996; 89(3):274-7. PubMed ID: 8675981
[No Abstract] [Full Text] [Related]
2. Molecular implications of the antiandrogen withdrawal syndrome.
Moul JW; Srivastava S; McLeod DG
Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
[No Abstract] [Full Text] [Related]
3. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
4. [Fulminant liver failure induced by flutamide].
Rodríguez Gómez SJ; Martínez Moreno J; Martín Arribas MI; Pérez Villoria A; De la Serna Higuera C; Betancourt González A
Rev Esp Enferm Dig; 2000 Jun; 92(6):411. PubMed ID: 10985104
[No Abstract] [Full Text] [Related]
5. [Antiandrogen withdrawal syndrome in hormone refractory metastatic prostate cancer].
Coutant G; Algayres JP; Dordain ML; Selle F; Le Berruyer PY; Bili H; Daly JP
Rev Med Interne; 1997; 18(9):732-4. PubMed ID: 9365728
[No Abstract] [Full Text] [Related]
6. Interstitial pneumonitis related to flutamide monotherapy for prostate cancer.
Nomura M; Sato H; Fujimoto N; Matsumoto T
Int J Urol; 2004 Sep; 11(9):798-800. PubMed ID: 15379950
[TBL] [Abstract][Full Text] [Related]
7. Flutamide induced lupus.
Reid MB; Glode LM
J Urol; 1998 Jun; 159(6):2098. PubMed ID: 9598538
[No Abstract] [Full Text] [Related]
8. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
9. Flutamide-induced photosensitivity: is it a forme fruste of lupus?
Kaur C; Thami GP
Br J Dermatol; 2003 Mar; 148(3):603-4. PubMed ID: 12653768
[No Abstract] [Full Text] [Related]
10. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.
Kelly WK
Eur Urol; 1998; 34 Suppl 3():18-23. PubMed ID: 9854191
[TBL] [Abstract][Full Text] [Related]
11. Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy.
Karamanakos P; Mitsiades CS; Lembessis P; Kontos M; Trafalis D; Koutsilieris M
Anticancer Res; 2004; 24(2C):1077-81. PubMed ID: 15154626
[TBL] [Abstract][Full Text] [Related]
12. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Kelly WK; Slovin S; Scher HI
Urol Clin North Am; 1997 May; 24(2):421-31. PubMed ID: 9126240
[TBL] [Abstract][Full Text] [Related]
13. Flutamide photosensitivity.
Leroy D; Dompmartin A; Szczurko C
Photodermatol Photoimmunol Photomed; 1996 Oct; 12(5):216-8. PubMed ID: 9112281
[TBL] [Abstract][Full Text] [Related]
14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
15. Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
Negi SS; Agarwal A; Chaudhary A
Invest New Drugs; 2006 May; 24(3):189-94. PubMed ID: 16133790
[TBL] [Abstract][Full Text] [Related]
16. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
[TBL] [Abstract][Full Text] [Related]
17. Is photopatch testing useful in the investigation of photosensitivity due to flutamide?
Martín-Lázaro J; Buján JG; Arrondo AP; Lozano JR; Galindo EC; Capdevila EF
Contact Dermatitis; 2004 May; 50(5):325-6. PubMed ID: 15209825
[No Abstract] [Full Text] [Related]
18. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
Sharma JJ; Razvillas B; Stephens CD; Hilsenbeck SG; Sharma A; Rothenberg ML
Invest New Drugs; 1997; 15(4):361-4. PubMed ID: 9547680
[TBL] [Abstract][Full Text] [Related]
19. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Sogani PC; Vagaiwala MR; Whitmore WF
Cancer; 1984 Aug; 54(4):744-50. PubMed ID: 6378356
[TBL] [Abstract][Full Text] [Related]
20. [Fulminant hepatitis associated with treatment with flutamide].
García-Gascó P; Morata Aldea C; Segura Huertas A; Aparicio Urtasun J
Med Clin (Barc); 1997 Dec; 109(20):820. PubMed ID: 9493166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
